Search
Medium-chain triglycerides
go.drugbank.com/drugs/DB13959ApprovedInvestigationalIn the body, MCTs are broken down into glycerol and free fatty acids, which are directly absorbed into the blood stream and transported to the target organs to exert a range of biological and metabolic … Medium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.
Mixtures: LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 100 ML, LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 250 MLSotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigational[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992.
Ribosome-binding protein 1
go.drugbank.com/bio_entities/BE0003466TargetHumansActs as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane
Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homologNatural killer cells antigen CD94
go.drugbank.com/bio_entities/BE0010559TargetHumansImmune receptor involved in self-nonself discrimination.
Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activityStreptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19344ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … pneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalThe phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … late-phase CINV during the first 120 hours post-chemotherapy.
Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor AntagonistPozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115]. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigational[A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725] … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms.
V-type immunoglobulin domain-containing suppressor of T-cell activation
go.drugbank.com/bio_entities/BE0010797TargetHumansImmunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity).
Synonyms: Platelet receptor Gi24, V-set immunoregulatory receptor